Table_1_Statin Use and the Risk of Prostate Cancer Biochemical Recurrence Following Definitive Therapy: A Systematic Review and Meta-Analysis of Cohort Studies.docx

BackgroundNumerous studies have reported the role of statins on biochemical recurrence (BCR) among patients with prostate cancer (PCa) after definite treatment. However, the conclusions of these studies are contradictory. We aimed to determine the effect of statins on BCR of PCa using a systematic review and meta-analysis.
MethodsWe searched PubMed (Medline) and other databases for cohort studies evaluating the effect of statins on the BCR of patients with PCa between January 1, 2000, and December 31, 2021. The random effects (RE) model and quality effects (QE) model were used to calculate the pooled hazard ratio (pHR) and pooled risk ratio (pRR) and their 95% confidence interval (95% CI).
ResultsA total of 33 cohort studies were finally selected and included in this systematic review and meta-analysis. Statin use was significantly associated with a 14% reduction in the HR of BCR (pHR: 0.86, 95% CI: 0.78 to 0.95, I2 = 64%, random effects model, 31 studies) and a 26% reduction in the RR of BCR (pRR: 0.74, 95% CI: 0.57 to 0.94, 24,591 patients, I2 = 88%, random effects model, 15 studies) among patients with PCa. The subgroup analyses showed that statins could result in 22% reduction in the HR of BCR (pHR: 0.78, 95% CI: 0.61 to 0.98, I2 = 57%, random effects model) among patients accepting radiotherapy (RT).
ConclusionsOur study suggests that statins have a unique role in the reduction of BCR in patients with PCa after definite treatment, especially RT. In the future, more clinical trials and in vitro and animal experiments are needed to further verify the effects of statins in PCa and the potential mechanisms.

## 背景
已有多项研究探讨了他汀类药物（statins）对确定性治疗后前列腺癌（PCa）患者生化复发（BCR）的影响，但此类研究结论尚存争议。本研究旨在通过系统评价与Meta分析，明确他汀类药物对前列腺癌患者生化复发的作用。
## 方法
我们检索了PubMed（Medline）及其他数据库，筛选2000年1月1日至2021年12月31日期间发表的、评估他汀类药物对前列腺癌患者生化复发影响的队列研究。采用随机效应（RE）模型与质量效应（QE）模型计算合并风险比（pHR）、合并相对危险度（pRR）及其95%置信区间（95%CI）。
## 结果
本系统评价与Meta分析最终纳入33项队列研究。分析显示，前列腺癌患者使用他汀类药物可使生化复发的风险比降低14%（合并风险比pHR=0.86，95%CI：0.78~0.95，I²=64%，随机效应模型，纳入31项研究），同时使生化复发的相对危险度降低26%（合并相对危险度pRR=0.74，95%CI：0.57~0.94，纳入24591例患者，I²=88%，随机效应模型，纳入15项研究）。亚组分析表明，在接受放疗（RT）的前列腺癌患者中，他汀类药物可使生化复发的风险比降低22%（pHR=0.78，95%CI：0.61~0.98，I²=57%，随机效应模型）。
## 结论
本研究表明，他汀类药物可有效降低确定性治疗后前列腺癌患者的生化复发风险，尤其对接受放疗的患者效果更为显著。未来需开展更多临床试验、体外实验及动物实验，以进一步验证他汀类药物在前列腺癌治疗中的作用及其潜在分子机制。